Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953742 · ClinicalTrials.gov registry record · Phase 1
Study of CPI-200 in Patients With Advanced Tumors
A Phase 1 study, sponsored by Coordination Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03953742 is a Phase 1 study that has completed, run by Coordination Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT03953742, a Phase 1 study, has completed, sponsored by Coordination Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a prospective, open-label, single arm, non-randomized study of CPI-200 in patients with advanced tumors. CPI-200 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD)
Interventions
- DRUG CPI-200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2022-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03953742
The ClinicalTrials.gov registry entry for NCT03953742 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coordination Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CPI-200 is the first listed.
NCT03953742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03953742 about?
NCT03953742 is a clinical study titled "Study of CPI-200 in Patients With Advanced Tumors". This is a prospective, open-label, single arm, non-randomized study of CPI-200 in patients with advanced tumors. CPI-200 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD)
What is the current status of trial NCT03953742?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2019-07-01. Estimated completion is 2022-02-15.
What interventions are being tested in trial NCT03953742?
The interventions under investigation include: CPI-200 (DRUG).
Who is sponsoring clinical trial NCT03953742?
This trial is sponsored by Coordination Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.